Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Molecular Mechanism of Qingchang Suppository in the Treatment of Ulcerative Colitis Based on Network Pharmacology

Author(s): Zhancheng Lin, Lu Lu and Lingyu Zhu*

Volume 20, Issue 1, 2023

Published on: 27 August, 2022

Page: [71 - 76] Pages: 6

DOI: 10.2174/1570180819666220509070003

Price: $65

conference banner
Abstract

Objective: The study aims to explore the mechanism of Qingchang Suppository in the treatment of ulcerative colitis from the perspective of network pharmacology.

Methods: The TCM Pharmacology database and analysis platform (TCMSP) were used to determine the effective components and related target information of the Qingchang Suppository. The main objective is to search the target genes related to ulcerative colitis using the GeneCards database. The target abbreviation is transformed into gene number by Perl language. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway was analyzed by R language. The pharmacological mechanism of Qingchang supply was discussed, laying the foundation for the next experiment.

Results: 869 indexes of Qingchang Suppository were determined. 368 targets of ulcerative colitis were obtained. Qingchang Suppository and ulcerative colitis were compared, and 141 overlapping targets were extracted. The "active ingredient target" network of Qingchang Suppository was constructed. The interaction between the effective components of Qingchang Suppository and the target of ulcerative colitis was revealed. The overlapping targets were analyzed for the KEGG pathway and function enrichment to explore the mechanism of Qingchang Suppository in the treatment of ulcerative colitis.

Conclusion: Qingchang Suppository has the characteristics of multi-component, multi-target and multichannel, which provide a new idea and basis for further study on the mechanism of Qingchang Suppository in the treatment of ulcerative colitis.

Keywords: Qingchang suppository, ulcerative colitis, network pharmacology, KEGG pathway, perl language, multi-target

« Previous Next »
[1]
Feng, Z.; Tang, X.G.; Shen, X.L. Theory of "Blood and Water Treatment at the Same Time" Method in the Treatment of Ulcerative Colitis. Journal of Chengdu University of Traditional Chinese Medicine, 2015.
[2]
Yu, T.; Li, Z.; Xu, L.; Yang, M.; Zhou, X. Anti-inflammation effect of Qingchang suppository in ulcerative colitis through JAK2/STAT3 signaling pathway in vitro and in vivo. J. Ethnopharmacol., 2021, 266, 113442.
[http://dx.doi.org/10.1016/j.jep.2020.113442] [PMID: 33027643]
[3]
Yang, Z.B.; Qiu, L.Z.; Chen, Q.; Lin, J.D. Artesunate alleviates the inflammatory response of ulcerative colitis by regulating the expression of miR-155. Pharm. Biol., 2021, 59(1), 97-105.
[http://dx.doi.org/10.1080/13880209.2020.1867196] [PMID: 33524272]
[4]
Burisch, J. Crohn’s disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan. Med. J., 2014, 61(1), B4778.
[PMID: 24393595]
[5]
Shi, B.; Xie, J.; Tao, Z.; Xu, H.; Yuan, J.; Yu, Z. Effect of qingchang suppository on the expression of its regulatory proteins Bcl-2 and Bax in an experimental models of ulcerative colitis; Henan Traditional Chinese Medicine, 2008.
[6]
Vissers, J.L.; Hartgers, F.C.; Lindhout, E.; Figdor, C.G.; Adema, G.J. BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur. J. Immunol., 2001, 31(5), 1544-1549.
[http://dx.doi.org/10.1002/1521-4141(200105)31:5<1544::AID-IMMU1544>3.0.CO;2-I] [PMID: 11465112]
[7]
Dai, Y.; Jiao, H.; Teng, G.; Wang, W.; Zhang, R.; Wang, Y.; Hebbard, L.; George, J.; Qiao, L. Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling. Mol. Cancer Ther., 2014, 13(5), 1206-1216.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0378] [PMID: 24651526]
[8]
Xia, M.; Zhu, J.L.; Chen, J.; Gastroenterology, D. The expression levels and clinical significances of LRG1,TGF-β and Smad2 in the colonic mucosa tissues of patients with ulcerative colitis. J. Clin. Exp. Med., 2018.
[9]
Zhou, H.L. Regulation of cell survival and apoptosis by phosphoinositide 3-kinase/Akt pathway. In: Pennsylvania Uo; , 2000.
[10]
Yao, J.; Wang, L.; Wang, J.; Li, Y.X.; Xun, A.; Wei, X. Effect of Resveratrol on Cytokines Expression in Colonic Mucosa of Mice with Ulcerative Colitis. Zhongyao Xinyao Yu Linchuang Yaoli, 2010.
[11]
Manning, C.; Gajewski, T.F. Cells of the monocyte/macrophage lineage, 2nd ed; Dendritic Cells, 2001, pp. 263-274.
[12]
Resta-Lenert, S.; Barrett, K.E. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology, 2006, 130(3), 731-746.
[http://dx.doi.org/10.1053/j.gastro.2005.12.015] [PMID: 16530515]
[13]
Matsui, K.; Wirotesangthong, M.; Nishikawa, A. Analysis of signaling pathways involved in peptidoglycan-induced RANTES production from murine Langerhans cells. Int. Arch. Allergy Immunol., 2009, 149(2), 167-172.
[http://dx.doi.org/10.1159/000189201] [PMID: 19127075]
[14]
Zhang, H.J.; Xu, B.; Wang, H.; Xu, B.; Wang, G.D.; Jiang, M.Z.; Lei, C.; Ding, M.L.; Yu, P.F.; Nie, Y.Z.; Wu, K.C.; Sha, S.M.; Li, M.B. IL-17 is a protection effector against the adherent-invasive Escherichia coli in murine colitis. Mol. Immunol., 2018, 93, 166-172.
[http://dx.doi.org/10.1016/j.molimm.2017.11.020] [PMID: 29195141]
[15]
Peckham, R.K.; Brill, R.; Foster, D.S.; Bowen, A.L.; Leigh, J.A.; Coffey, T.J.; Flynn, R.J. Two distinct populations of bovine IL-17+ T-cells can be induced and WC1+IL-17+γδ T-cells are effective killers of protozoan parasites. Sci. Rep., 2014, 4, 5431.
[http://dx.doi.org/10.1038/srep05431] [PMID: 24961164]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy